Pulse Biosciences, Inc.
PLSE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -4.17 | 0.29 | 0.07 | -0.99 |
| FCF Yield | -3.59% | -5.64% | -50.44% | -13.17% |
| EV / EBITDA | -17.32 | -13.05 | -1.92 | -6.41 |
| Quality | ||||
| ROIC | -43.92% | -81.44% | -78.77% | -134.24% |
| Gross Margin | 0.00% | 0.00% | -1,606.29% | -38.79% |
| Cash Conversion Ratio | 0.68 | 0.78 | 0.80 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | – | – |
| Free Cash Flow Growth | -9.97% | 30.06% | 13.06% | -52.30% |
| Safety | ||||
| Net Debt / EBITDA | 2.08 | 0.83 | -0.26 | 0.28 |
| Interest Coverage | 0.00 | -39.61 | -129.59 | -97.54 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.34 |
| Cash Conversion Cycle | -518.37 | -555.21 | -48.07 | 557.27 |